Circulating levels and clinical significance of soluble CD86 in myeloma patients

British Journal of Haematology

Volumn 133, Issue 2, 2006, Pages 165-172

  Hock, B D ^a,c   Drayson, M ^b   Patton, W N ^a   Taylor, K ^a   Kerr, L ^a   McKenzie, J L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CD86; Myeloma; Prednisolone; Serum; Soluble

Indexed keywords

CARMUSTINE; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; ARTICLE; CIRCULATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; MYELOMA; PATIENT; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL; UNITED KINGDOM; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIGENS, CD86; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISOLONE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33645077055     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.05983.x     Document Type: Article

References (24)

1. Egen J.G. Kuhns M.S. Allison J.P. 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nature Immunology 3 611 618
2. Finger E.B. Bluestone J.A. 2002 When ligand becomes receptor-tolerance via B7 signaling on DCs Nature Immunology 3 1056 1057
3. Flo J. Tisminetzky S. Baralle F. 2001 Codelivery of DNA coding for the soluble form of CD86 results in the down-regulation of the immune response to DNA vaccines Cellular Immunology 209 120 131
4. Freeman G.J. Gribben J.G. Boussiotis V.A. Ng J.W. Restivo Jr. V.A. Lombard L.A Gray G.S. Nadler L.M. 1993 Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 909 911
5. Gerstmayer B. Pessara U. Wels W. 1997 Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4 FEBS Letters 407 63 68
6. Greipp P.R. San Miguel J. Durie B.G. Crowley J.J. Barlogie B. Blade J. Boccadoro M. Child J.A. Avet-Loiseau H. Kyle R.A. Lahuerta J.J. Ludwig H. Morgan G. Powles R. Shimizu K. Shustik C. Sonneveld P. Tosi P. Turesson I. Westin J. 2005 International staging system for multiple myeloma Journal of Clinical Oncology 23 3412 3420
7. Hirano N. Takahashi T. Ohtake S. Hirashima K. Emi N. Saito K. Hirano M. Shinohara K. Takeuchi M. Taketazu F. Tsunoda S. Ogura M. Omine M. Saito T. Yazaki Y. Ueda R. Hirai H. 1996 Expression of costimulatory molecules in human leukemias Leukemia 10 1168 1176
8. Hock B.D. Patton W.N. Budhia S. Mannari D. Roberts P. McKenzie J.L. 2002 Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients Leukemia 16 865 873
9. Hock B.D. McKenzie J.L. Patton W.N. Haring L.F. Yang Y. Shen Y. Estey E.H. Albitar M. 2003 The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome Cancer 98 1681 1688
10. Hodi F.S. Mihm M.C. Soiffer R.J. Haluska F.G. Butler M. Seiden M.V. Davis T. Henry-Spires R. MacRae S. Willman A. Padera R. Jaklitsch M.T. Shankar S. Chen T.C. Korman A. Allison J.P. Dranoff G. 2003 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proceedings of the National Academy of Sciences of the United States of America 100 4712 4717
11. Jacobson J. Barlogie B. Shaughnessy J. Drach J. Tricot G. Fassas A. Zangari M. Giroux D. Crowley J. Hough A. Sawyer J. 2003 MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants British Journal of Haematology 122 430 440
12. Jeannin P. Magistrelli G. Aubry J.P. Caron G. Gauchat J.F. Renno T. Herbault N. Goetsch L. Blaecke A. Dietrich P.Y. Bonnefoy J.Y. Delneste Y. 2000 Soluble CD86 is a costimulatory molecule for human T lymphocytes Immunity 13 303 312
13. Lenschow D.J. Walunas T.L. Bluestone J.A. 1996 CD28/B7 system of T cell costimulation Annual Review of Immunology 14 233 258
14. Maeda A. Yamamoto K. Yamashita K. Asagoe K. Nohgawa M. Kita K. Iwasaki H. Ueda T. Takahashi A. Sasada M. 1998 The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2- positive leukaemia British Journal of Haematology 102 1257 1262
15. McKay L.C. Cidlowski J. 2003 Corticosteroids In: Holland-Frei Cancer Medicine 6 ed. by Kufe D.P. Weichselbaum R. Bast R. Gansler T. Holland J. Frei E. pp 927 938 BC Decker Hamilton, Ontario
16. Olujohungbe A.B. Dunn J.A. Drayson M.T. McLennan I.C.M 1996 Prednisolone added to the ABCM as treatment for multiple myeloma increases serological responses but not overall survival or the number of stable clinical responses British Journal of Haematology 93 Suppl. 1 77
17. Orabona C. Grohmann U. Belladonna M.L. Fallarino F. Vacca C. Bianchi R. Bozza S. Volpi C. Salomon B.L. Fioretti M.C. Romani L. Puccetti P. 2004 CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86 Nature Immunology 5 1134 1142
18. Pope B. Brown R.D. Gibson J. Yuen E. Joshua D. 2000 B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy Blood 96 1274 1279
19. Rennert P. Furlong K. Jellis C. Greenfield E. Freeman G.J. Ueda Y. Levine B. June C.H. Gray G.S. 1997 The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion International Immunology 9 805 813
20. Runyon K. Lee K. Zuberek K. Collins M. Leonard J.P. Dunussi-Joannopoulos K. 2001 The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses Blood 97 2420 2426
21. Sharpe A.H. Freeman G.J. 2002 The B7-CD28 superfamily Nature Reviews in Immunology 2 116 126
22. Sirohi B. Powles R. 2004 Multiple myeloma Lancet 363 875 887
23. Sturmhoefel K. Lee K. Gray G.S. Thomas J. Zollner R. O'Toole M. Swiniarski H. Dorner A. Wolf S.F. 1999 Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant Cancer Research 59 4964 4972
24. Zheng Z. Takahashi M. Aoki S. Toba K. Liu A. Osman Y. Takahashi H. Tsukada N. Suzuki N. Nikkuni K. Furukawa T. Koike T. Aizawa Y. 1998 Expression patterns of costimulatory molecules on cells derived from human hematological malignancies Journal of Experimental and Clinical Cancer Research 17 251 258